A Phase 1 Non-randomized/2 Randomized Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies

Trial Profile

A Phase 1 Non-randomized/2 Randomized Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Programmed cellular immunotherapeutic (Primary)
  • Indications Cytomegalovirus infections; Graft-versus-host disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 18 Sep 2017 According to a Fate Therapeutics media release, Based on the review of phase 1 data, independent data monitoring committee recommended initiation of the randomized, controlled and blinded Phase 2 stage of this trial.
    • 18 Sep 2017 According to a Fate Therapeutics media release, Once all seven Phase 1 subjects progress to Day 100 post-HCT, we expect to present ProTmune Day 100 efficacy data, including acute GvHD, cancer relapse and survival, at the 2017 American Society of Hematology annual meeting.
    • 18 Sep 2017 According to a Fate Therapeutics media release, enrollment in phase 2 stage of this trial has been initiated. Thirteen U.S. centers are currently open for enrollment in the Phase 2 stage of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top